drugset / Trial / NCT01306162

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

NCT01306162

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study is to assess the relative bioavailability of a single dose of dabigatran after concomitant multiple oral administration of dronedarone with the aim to investigate whether and to what extent the P-gp inhibitor dronedarone affects pharmacokinetic parameters of dabigatran when administered to healthy subjects

Timeline

Start
2011-02
Primary completion
2011-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral
Subject Dronedarone Small molecule 400 mg Oral

Indications

No indication recorded.